Aminoguanidine inhibits the development of accelerated diabetic retinopathy in the spontaneous hypertensive rat

H. P. Hammes, M. Brownlee, D. Edelstein, M. Saleck, S. Martin, K. Federlin

Research output: Contribution to journalArticle

106 Citations (Scopus)

Abstract

Arterial hypertension has been identified as a major secondary risk factor for diabetic retinopathy. However, the mechanisms by which hypertension worsens retinopathy are unknown. Inhibition of advanced glycation product formation prevents the development of experimental diabetic retinopathy in normotensive diabetic rats. In this study the effect of hypertension on the rate of diabetic retinopathy development and the formation of arteriolar thrombosis was evaluated. We also evaluated the effect of aminoguanidine, an inhibitor of advanced glycation end product formation on retinal pathology of diabetic hypertensive rats. After 26 weeks of diabetes, hypertension accelerated the development of retinopathy despite a lower mean blood glucose level than in the non-hypertensive group (diabetic spontaneous hypertensive rats (SHR) 16.00±6.83 mmol/l; diabetic normotensive Wistar Kyoto rats (WKY) 34.9±3.64 mmol/l; p<0.0001). Diabetic SHR had nearly twice as many acellular capillaries as diabetic WKY (SHR diabetic: 91.9±7.5 acellular capillaries per mm2 of retinal area vs WKY diabetic: 53.7±8.5 acellular capillaries per mm2 of retinal area), and a 3.8-fold increase in the number of arteriolar microthromboses (SHR diabetic 23504±5523 μm2 vs SHR non-diabetic 6228±2707 μm2). Aminoguanidine treatment of SHR diabetic rats reduced the number of acellular capillaries by 50%, and completely prevented both arteriolar deposition of PAS-positive material and abnormal microthrombus formation. These data suggest that hypertension-induced deposition of glycated proteins in the retinal vasculature plays a central role in the acceleration of diabetic retinopathy by hypertension.

Original languageEnglish (US)
Pages (from-to)32-35
Number of pages4
JournalDiabetologia
Volume37
Issue number1
DOIs
StatePublished - Jan 1994

Fingerprint

Diabetic Retinopathy
Hypertension
Inbred WKY Rats
pimagedine
Advanced Glycosylation End Products
Blood Glucose
Thrombosis
Pathology

Keywords

  • aminoguanidine
  • Diabetic retinopathy
  • glycation
  • hypertension
  • rat model
  • SHR

ASJC Scopus subject areas

  • Internal Medicine
  • Endocrinology, Diabetes and Metabolism

Cite this

Hammes, H. P., Brownlee, M., Edelstein, D., Saleck, M., Martin, S., & Federlin, K. (1994). Aminoguanidine inhibits the development of accelerated diabetic retinopathy in the spontaneous hypertensive rat. Diabetologia, 37(1), 32-35. https://doi.org/10.1007/BF00428774

Aminoguanidine inhibits the development of accelerated diabetic retinopathy in the spontaneous hypertensive rat. / Hammes, H. P.; Brownlee, M.; Edelstein, D.; Saleck, M.; Martin, S.; Federlin, K.

In: Diabetologia, Vol. 37, No. 1, 01.1994, p. 32-35.

Research output: Contribution to journalArticle

Hammes, HP, Brownlee, M, Edelstein, D, Saleck, M, Martin, S & Federlin, K 1994, 'Aminoguanidine inhibits the development of accelerated diabetic retinopathy in the spontaneous hypertensive rat', Diabetologia, vol. 37, no. 1, pp. 32-35. https://doi.org/10.1007/BF00428774
Hammes, H. P. ; Brownlee, M. ; Edelstein, D. ; Saleck, M. ; Martin, S. ; Federlin, K. / Aminoguanidine inhibits the development of accelerated diabetic retinopathy in the spontaneous hypertensive rat. In: Diabetologia. 1994 ; Vol. 37, No. 1. pp. 32-35.
@article{f38c41fd9a5c49c0b31ef888fbbf9f96,
title = "Aminoguanidine inhibits the development of accelerated diabetic retinopathy in the spontaneous hypertensive rat",
abstract = "Arterial hypertension has been identified as a major secondary risk factor for diabetic retinopathy. However, the mechanisms by which hypertension worsens retinopathy are unknown. Inhibition of advanced glycation product formation prevents the development of experimental diabetic retinopathy in normotensive diabetic rats. In this study the effect of hypertension on the rate of diabetic retinopathy development and the formation of arteriolar thrombosis was evaluated. We also evaluated the effect of aminoguanidine, an inhibitor of advanced glycation end product formation on retinal pathology of diabetic hypertensive rats. After 26 weeks of diabetes, hypertension accelerated the development of retinopathy despite a lower mean blood glucose level than in the non-hypertensive group (diabetic spontaneous hypertensive rats (SHR) 16.00±6.83 mmol/l; diabetic normotensive Wistar Kyoto rats (WKY) 34.9±3.64 mmol/l; p<0.0001). Diabetic SHR had nearly twice as many acellular capillaries as diabetic WKY (SHR diabetic: 91.9±7.5 acellular capillaries per mm2 of retinal area vs WKY diabetic: 53.7±8.5 acellular capillaries per mm2 of retinal area), and a 3.8-fold increase in the number of arteriolar microthromboses (SHR diabetic 23504±5523 μm2 vs SHR non-diabetic 6228±2707 μm2). Aminoguanidine treatment of SHR diabetic rats reduced the number of acellular capillaries by 50{\%}, and completely prevented both arteriolar deposition of PAS-positive material and abnormal microthrombus formation. These data suggest that hypertension-induced deposition of glycated proteins in the retinal vasculature plays a central role in the acceleration of diabetic retinopathy by hypertension.",
keywords = "aminoguanidine, Diabetic retinopathy, glycation, hypertension, rat model, SHR",
author = "Hammes, {H. P.} and M. Brownlee and D. Edelstein and M. Saleck and S. Martin and K. Federlin",
year = "1994",
month = "1",
doi = "10.1007/BF00428774",
language = "English (US)",
volume = "37",
pages = "32--35",
journal = "Diabetologia",
issn = "0012-186X",
publisher = "Springer Verlag",
number = "1",

}

TY - JOUR

T1 - Aminoguanidine inhibits the development of accelerated diabetic retinopathy in the spontaneous hypertensive rat

AU - Hammes, H. P.

AU - Brownlee, M.

AU - Edelstein, D.

AU - Saleck, M.

AU - Martin, S.

AU - Federlin, K.

PY - 1994/1

Y1 - 1994/1

N2 - Arterial hypertension has been identified as a major secondary risk factor for diabetic retinopathy. However, the mechanisms by which hypertension worsens retinopathy are unknown. Inhibition of advanced glycation product formation prevents the development of experimental diabetic retinopathy in normotensive diabetic rats. In this study the effect of hypertension on the rate of diabetic retinopathy development and the formation of arteriolar thrombosis was evaluated. We also evaluated the effect of aminoguanidine, an inhibitor of advanced glycation end product formation on retinal pathology of diabetic hypertensive rats. After 26 weeks of diabetes, hypertension accelerated the development of retinopathy despite a lower mean blood glucose level than in the non-hypertensive group (diabetic spontaneous hypertensive rats (SHR) 16.00±6.83 mmol/l; diabetic normotensive Wistar Kyoto rats (WKY) 34.9±3.64 mmol/l; p<0.0001). Diabetic SHR had nearly twice as many acellular capillaries as diabetic WKY (SHR diabetic: 91.9±7.5 acellular capillaries per mm2 of retinal area vs WKY diabetic: 53.7±8.5 acellular capillaries per mm2 of retinal area), and a 3.8-fold increase in the number of arteriolar microthromboses (SHR diabetic 23504±5523 μm2 vs SHR non-diabetic 6228±2707 μm2). Aminoguanidine treatment of SHR diabetic rats reduced the number of acellular capillaries by 50%, and completely prevented both arteriolar deposition of PAS-positive material and abnormal microthrombus formation. These data suggest that hypertension-induced deposition of glycated proteins in the retinal vasculature plays a central role in the acceleration of diabetic retinopathy by hypertension.

AB - Arterial hypertension has been identified as a major secondary risk factor for diabetic retinopathy. However, the mechanisms by which hypertension worsens retinopathy are unknown. Inhibition of advanced glycation product formation prevents the development of experimental diabetic retinopathy in normotensive diabetic rats. In this study the effect of hypertension on the rate of diabetic retinopathy development and the formation of arteriolar thrombosis was evaluated. We also evaluated the effect of aminoguanidine, an inhibitor of advanced glycation end product formation on retinal pathology of diabetic hypertensive rats. After 26 weeks of diabetes, hypertension accelerated the development of retinopathy despite a lower mean blood glucose level than in the non-hypertensive group (diabetic spontaneous hypertensive rats (SHR) 16.00±6.83 mmol/l; diabetic normotensive Wistar Kyoto rats (WKY) 34.9±3.64 mmol/l; p<0.0001). Diabetic SHR had nearly twice as many acellular capillaries as diabetic WKY (SHR diabetic: 91.9±7.5 acellular capillaries per mm2 of retinal area vs WKY diabetic: 53.7±8.5 acellular capillaries per mm2 of retinal area), and a 3.8-fold increase in the number of arteriolar microthromboses (SHR diabetic 23504±5523 μm2 vs SHR non-diabetic 6228±2707 μm2). Aminoguanidine treatment of SHR diabetic rats reduced the number of acellular capillaries by 50%, and completely prevented both arteriolar deposition of PAS-positive material and abnormal microthrombus formation. These data suggest that hypertension-induced deposition of glycated proteins in the retinal vasculature plays a central role in the acceleration of diabetic retinopathy by hypertension.

KW - aminoguanidine

KW - Diabetic retinopathy

KW - glycation

KW - hypertension

KW - rat model

KW - SHR

UR - http://www.scopus.com/inward/record.url?scp=0028107538&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0028107538&partnerID=8YFLogxK

U2 - 10.1007/BF00428774

DO - 10.1007/BF00428774

M3 - Article

VL - 37

SP - 32

EP - 35

JO - Diabetologia

JF - Diabetologia

SN - 0012-186X

IS - 1

ER -